Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2011 3
2012 1
2013 2
2014 1
2015 3
2016 1
2017 3
2018 4
2019 1
2020 4
2021 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group. Waters L, et al. Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827. Clin Infect Dis. 2023. PMID: 36259527 Clinical Trial.
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT022 Study Group. González-Cordón A, et al. J Antimicrob Chemother. 2021 Aug 12;76(9):2380-2393. doi: 10.1093/jac/dkab158. J Antimicrob Chemother. 2021. PMID: 34120186 Clinical Trial.
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.
Gonzalez-Cordon A, Assoumou L, Camafort M, Domenech M, Guaraldi G, Domingo P, Rusconi S, Raffi F, Katlama C, Masia M, Bernardino JI, Saumoy M, Pozniak A, Gatell JM, Martinez E; NEAT022 Study Group. Gonzalez-Cordon A, et al. J Antimicrob Chemother. 2020 Nov 1;75(11):3334-3343. doi: 10.1093/jac/dkaa292. J Antimicrob Chemother. 2020. PMID: 32737482 Clinical Trial.
Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.
André-Garnier E, Hingrat QL, Marcelin AG, Reliquet V, Malet I, Leducq V, Rodallec A, Peytavin G, Ferré V, Charpentier C, Raffi F. André-Garnier E, et al. Among authors: rodallec a. Int J Antimicrob Agents. 2020 Aug;56(2):106039. doi: 10.1016/j.ijantimicag.2020.106039. Epub 2020 May 29. Int J Antimicrob Agents. 2020. PMID: 32479891 No abstract available.
Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?
Frange P, Tubiana R, Sibiude J, Canestri A, Arvieux C, Brunet-Cartier C, Cotte L, Reynes J, Mandelbrot L, Warszawski J, Le Chenadec J; ANRS EPF CO1/CO11 Study Group. Frange P, et al. J Antimicrob Chemother. 2020 May 1;75(5):1324-1331. doi: 10.1093/jac/dkaa017. J Antimicrob Chemother. 2020. PMID: 32157283
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.
Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group. Gatell JM, et al. Clin Infect Dis. 2019 Feb 1;68(4):597-606. doi: 10.1093/cid/ciy505. Clin Infect Dis. 2019. PMID: 29912307 Clinical Trial.
Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).
Lambert-Niclot S, Grude M, Chaix ML, Charpentier C, Reigadas S, Le Guillou-Guillemette H, Rodallec A, Amiel C, Maillard A, Dufayard J, Mourez T, Mirand A, Guinard J, Montes B, Vallet S, Marcelin AG, Descamps D, Flandre P, Delaugerre C, Morand-Joubert L; ANRS AC-11 Resistance Group. Lambert-Niclot S, et al. J Antimicrob Chemother. 2018 Aug 1;73(8):2147-2151. doi: 10.1093/jac/dky142. J Antimicrob Chemother. 2018. PMID: 29718247
HCMV triggers frequent and persistent UL40-specific unconventional HLA-E-restricted CD8 T-cell responses with potential autologous and allogeneic peptide recognition.
Jouand N, Bressollette-Bodin C, Gérard N, Giral M, Guérif P, Rodallec A, Oger R, Parrot T, Allard M, Cesbron-Gautier A, Gervois N, Charreau B. Jouand N, et al. Among authors: rodallec a. PLoS Pathog. 2018 Apr 30;14(4):e1007041. doi: 10.1371/journal.ppat.1007041. eCollection 2018 Apr. PLoS Pathog. 2018. PMID: 29709038 Free PMC article.
26 results